Addington, Jean, Liu, Lu, Chu, Monica, Jungert, Karl, Penzel, Nora, Pasternak, Ofer, Farina, Emily, Carrion, Ricardo E., Corcoran, Cheryl M., Mittal, Vijay A., Strauss, Gregory P., Yung, Alison R., Alameda, Luis, Arango, Celso, Borders, Owen, Bouix, Sylvain, Breitborde, Nicholas J. K., Broome, Matthew R., Cadenhead, Kristin S., Castillo-Passi, Rolando I., Chen, Eric Yu Hai, Choi, Jimmy, Coleman, Michael J., Conus, Philippe, Diaz-Caneja, Covadonga M., Ellman, Lauren M., Poli, Paolo Fusar, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Horton, Leslie E., Hui, Christy Lai Ming, Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kapur, Tina, Kelly, Sinead, Kerr, Melissa J., Keshavan, Matcheri S., Kim, Minah, Kim, Sung-Wan, Koutsouleris, Nikolaos, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., Mourgues, Catalina, Nordentoft, Merete, Nunez, Angela R., Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Rogers, Jack, Sabb, Fred W., Schiffman, Jason, Seitz-Holland, Johanna, Shah, Jai L., Silverstein, Steven M., Smesny, Stefan, Stone, William S., Thompson, Judy L., Upthegrove, Rachel, Verma, Swapna, Wang, Jijun, Wolf, Daniel H., Zhang, Tianhong, Addamo, Lauren, Buccilli, Kate, Dwyer, Dominic, Todd, Sophie, Cho, Youngsun T., Fontenau, Clara, Tamayo, Zailyn, Bearden, Carrie E., Kane, John M., McGorry, Patrick D., Kahn, Rene S., Shenton, Martha E., Woods, Scott W. et Calkins, Monica E..
2025.
« Baseline clinical characterization of participants in the accelerating medicines partnership schizophrenia program ».
Schizophrenia Bulletin Open, vol. 6, nº 1.
Prévisualisation |
PDF
Bouix-S-2025-31942.pdf - Version publiée Licence d'utilisation : Creative Commons CC BY. Télécharger (1MB) | Prévisualisation |
Résumé
Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.
| Type de document: | Article publié dans une revue, révisé par les pairs |
|---|---|
| Informations complémentaires: | Accelerating Medicines Partnership® Schizophrenia Nelson, Barnaby |
| Professeur: | Professeur Bouix, Sylvain |
| Affiliation: | Génie logiciel et des technologies de l'information |
| Date de dépôt: | 19 sept. 2025 13:34 |
| Dernière modification: | 25 sept. 2025 00:15 |
| URI: | https://espace2.etsmtl.ca/id/eprint/31942 |
Actions (Authentification requise)
 |
Dernière vérification avant le dépôt |